KBIO Investigation

Levi & Korsinsky, LLP announces that it has commenced an investigation of KaloBios Pharmaceuticals, Inc. (“KaloBios” or the “Company”) (NASDAQGM: KBIO) concerning possible violations of federal securities laws by the Company and/or certain of its officers and directors. On December 17, 2015, news outlets reported that Martin Shkreli, the CEO of KaloBios, was arrested on securities fraud charges relating to his illegal use of stock from Retrophin Inc. to pay off debts associated with other unrelated business ventures. On this news, KaloBios shares plummeted pre-market, and trading has since been halted.

To get more information regarding the investigation of KaloBios Pharmaceuticals, Inc., without cost or obligation, please call us at 415-373-1671 or complete our contact form.

The submission of this form does not create an attorney-client relationship automatically. Any information you submit will be maintained as confidential. If Levi & Korsinsky LLP, in its sole discretion, believes that you might have a claim, Levi & Korsinsky LLP will contact you to discuss the matter and whether to establish an attorney client relationship.